In 2014 Merck KGaA acquired Sigma-Aldrich Corp. for approximately $17 billion.
On December, 14 2009 Merck KGaA filed a patent application citing Abituzumab as a novel treatment and diagnostic tool for patients with tumor induced angiogenesis or another angiogenic-associated disorder.